borderline significantp = 0.05
The primary endpoint, a reduction in DGF from 26.5 to 20.8%, was only borderline significant ( p = 0.05) when one-sided statistical tests were used in the analysis.
The primary endpoint, a reduction in DGF from 26.5 to 20.8%, was only borderline significant ( p = 0.05) when one-sided statistical tests were used in the analysis.
The trial was terminated prematurely after an interim analysis showed highly significant efficacy after the enrolment of 370 of the planned 500 donors.